Isofol Medical AB (publ) (ISOFOL.ST)
SEK 1.93
(3.66%)
SEK 1.93
(3.66%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.16 Million SEK | -65.15% |
| 2022 | 54.98 Million SEK | -33.86% |
| 2021 | 83.13 Million SEK | 1.92% |
| 2020 | 81.56 Million SEK | 96.24% |
| 2019 | 41.56 Million SEK | 76.53% |
| 2018 | 23.54 Million SEK | 29.06% |
| 2017 | 18.24 Million SEK | 8.65% |
| 2016 | 16.79 Million SEK | 98.59% |
| 2015 | 8.45 Million SEK | 0.0% |
| 2011 | 2.48 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 19.08 Million SEK | -0.39% |
| 2024 Q2 | 21.96 Million SEK | 15.06% |
| 2023 Q1 | 28.01 Million SEK | -49.06% |
| 2023 Q2 | 25.25 Million SEK | -9.84% |
| 2023 Q3 | 19.81 Million SEK | -21.53% |
| 2023 Q4 | 19.16 Million SEK | -3.3% |
| 2023 FY | 19.16 Million SEK | -65.15% |
| 2022 Q2 | 82.23 Million SEK | 2.53% |
| 2022 Q1 | 80.2 Million SEK | -3.52% |
| 2022 FY | 54.98 Million SEK | -33.86% |
| 2022 Q4 | 54.98 Million SEK | -23.89% |
| 2022 Q3 | 72.24 Million SEK | -12.15% |
| 2021 Q3 | 74.52 Million SEK | -42.21% |
| 2021 Q1 | 81.52 Million SEK | -0.05% |
| 2021 Q2 | 128.95 Million SEK | 58.18% |
| 2021 FY | 83.13 Million SEK | 1.92% |
| 2021 Q4 | 83.13 Million SEK | 11.55% |
| 2020 FY | 81.56 Million SEK | 96.24% |
| 2020 Q4 | 81.56 Million SEK | 22.88% |
| 2020 Q2 | 58.6 Million SEK | 27.19% |
| 2020 Q1 | 46.07 Million SEK | 10.86% |
| 2020 Q3 | 66.37 Million SEK | 13.26% |
| 2019 Q3 | 44.92 Million SEK | 30.42% |
| 2019 Q2 | 34.44 Million SEK | 19.34% |
| 2019 FY | 41.56 Million SEK | 76.53% |
| 2019 Q4 | 41.56 Million SEK | -7.48% |
| 2019 Q1 | 28.86 Million SEK | 22.59% |
| 2018 Q1 | 16.8 Million SEK | -7.86% |
| 2018 Q2 | 10.4 Million SEK | -38.12% |
| 2018 Q4 | 23.54 Million SEK | 113.2% |
| 2018 FY | 23.54 Million SEK | 29.06% |
| 2018 Q3 | 11.04 Million SEK | 6.16% |
| 2017 Q1 | 7.56 Million SEK | -54.95% |
| 2017 FY | 18.24 Million SEK | 8.65% |
| 2017 Q4 | 18.24 Million SEK | 107.5% |
| 2017 Q3 | 8.79 Million SEK | -14.87% |
| 2017 Q2 | 10.32 Million SEK | 36.52% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | 16.79 Million SEK | 0.0% |
| 2016 FY | 16.79 Million SEK | 98.59% |
| 2015 Q4 | 8.45 Million SEK | 0.0% |
| 2015 FY | 8.45 Million SEK | 0.0% |
| 2011 FY | 2.48 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 4.42 Million SEK | -332.987% |
| BioArctic AB (publ) | 139.5 Million SEK | 86.263% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -712.378% |
| CombiGene AB (publ) | 4.15 Million SEK | -361.117% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 73.053% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -39.156% |
| OncoZenge AB (publ) | 1.69 Million SEK | -1027.958% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 82.022% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.776% |
| Mendus AB (publ) | 51.22 Million SEK | 62.589% |
| LIDDS AB (publ) | 3.75 Million SEK | -410.224% |
| Lipum AB (publ) | 7.53 Million SEK | -154.232% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 84.543% |
| Simris Alg AB (publ) | 148.93 Million SEK | 87.133% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -64.244% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -268.897% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.025% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 73.328% |
| Ziccum AB (publ) | 6.38 Million SEK | -200.0% |
| AcouSort AB (publ) | 10.37 Million SEK | -84.66% |
| Active Biotech AB (publ) | 13.4 Million SEK | -43.015% |
| Alzinova AB (publ) | 9.33 Million SEK | -105.38% |
| Amniotics AB (publ) | 10.54 Million SEK | -81.701% |
| Camurus AB (publ) | 414.81 Million SEK | 95.38% |
| Cantargia AB (publ) | 54.97 Million SEK | 65.137% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -399.323% |
| Genovis AB (publ.) | 98.04 Million SEK | 80.454% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -3.623% |
| Intervacc AB (publ) | 21.68 Million SEK | 11.605% |
| Kancera AB (publ) | 17.97 Million SEK | -6.597% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -65.65% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -271.539% |
| NextCell Pharma AB | 13.68 Million SEK | -39.995% |
| Saniona AB (publ) | 86.08 Million SEK | 77.738% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 53.097% |
| Xintela AB (publ) | 14.01 Million SEK | -36.739% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 44.618% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 28.246% |
| Corline Biomedical AB | 6.78 Million SEK | -182.28% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 68.766% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -18.906% |
| Aptahem AB (publ) | 8.99 Million SEK | -112.985% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 58.502% |
| Fluicell AB (publ) | 8.91 Million SEK | -114.964% |
| Biovica International AB (publ) | 34.76 Million SEK | 44.879% |
| Abliva AB (publ) | 16.78 Million SEK | -14.201% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 91.07% |
| 2cureX AB (publ) | 2.93 Million SEK | -552.947% |
| I-Tech AB | 16.2 Million SEK | -18.26% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.384% |
| Cyxone AB (publ) | 4.69 Million SEK | -308.266% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -43.788% |
| Biosergen AB | 5.08 Million SEK | -276.873% |
| Nanologica AB (publ) | 79.32 Million SEK | 75.842% |
| SynAct Pharma AB | 51.83 Million SEK | 63.028% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -141.087% |
| BioInvent International AB (publ) | 90.45 Million SEK | 78.813% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 89.447% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -968.227% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -50.377% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -163.967% |